eBook - PDF
New Aspects in Diabetes
Treatment Strategies with Alpha-Glucosidase Inhibitors. Third International Symposium on Acarbose
- 306 pages
- English
- PDF
- Available on iOS & Android
eBook - PDF
New Aspects in Diabetes
Treatment Strategies with Alpha-Glucosidase Inhibitors. Third International Symposium on Acarbose
Frequently asked questions
Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access New Aspects in Diabetes by Pierre J. Lefèbvre, Eberhard Standl in PDF and/or ePUB format, as well as other popular books in Medicine & Endocrinology & Metabolism. We have over one million books available in our catalogue for you to explore.
Information
Table of contents
- List of first-mentioned contributors
- Contents
- Introduction
- I. New aspects in diabetes mellitus
- The epidemiology of diabetes mellitus and its relationship with cardiovascular disease
- Syndrome X: fact or fiction?
- Strategies for the treatment of hyperglycemia in Syndrome X
- Treatment strategies of Syndrome X — hypertension and vascular complications
- Lipid metabolism: metabolic consequences of moderate hypertriglyceridemia
- Update on the treatment of NIDDM
- Hyperinsulinemia and macrovascular complications in NIDDM
- II. Quality of life in diabetes mellitus
- Diabetes and quality of life: some current issues in definition and research
- Quality of life in patients with type II diabetes mellitus
- Well-being in non-insulin-dependent diabetic patients (NIDDM) - a long-term follow-up
- III. Studies with acarbose
- Acarbose monotherapy in non-insulin-dependent diabetes mellitus — the German experience
- Acarbose in non-insulin-dependent diabetes mellitus: combination with sulfonylureas and interaction with diet
- Clinical efficacy of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus (NIDDM) — a placebo-controlled double-blind comparative study
- Effects of long-term administration of acarbose in patients with NIDDM - a double-blind study with placebo
- Effects of acarbose on blood glucose control in insulindependent diabetes mellitus
- European experience in the treatment of IDDM with acarbose in combination with insulin
- Round table discussion on open questions and future aspects
- IV. Abstracts
- A multi-center, double-blind, placebo-controlled study of the long-term efficacy and safety of acarbose (BAYg 5421) in the treatment of obese patients with NIDDM treated by diet alone
- A multi-center, double-blind, placebo-controlled study of long-term efficacy and safety of acarbose (BAY g 5421) and sulfonylureas in the treatment of NIDDM inadequately controlled by maximal doses of sulfonylureas (SFU)
- A multi-center, double-blind, comparative study of the long-term efficacy and safety of acarbose (BAY g 5421) vs. placebo in the treatment of patients with insulin requiring type II diabetes mellitus
- Prospective, multi-center studies of the efficacy and safety of acarbose (BAY g 5421) in the treatment of type I diabetes mellitus
- Two multi-center, double-blind, placebo-controlled studies of efficacy and safety of acarbose treatment of type I diabetes
- Clinical study of reduced postprandial hyperglycemia by acarbose and glycemic impact of fructose and sucrose in insulin therapy
- 6 months monotherapy of NIDDM with acarbose or glibenclamide
- Decreased insulin requirement and postprandial insulin plasma concentrations under treatment with the a-glucosidase inhibitor acarbose
- Long-term treatment of BAY g 5421 (acarbose) in noninsulin- dependent diabetes mellitus
- Clinical efficacy and tolerability of acarbose in IDDM treatment
- Effects of acarbose on the glycemic index of different foods
- Effects of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in type II diabetics
- Influence of acarbose on the release of gastrointestinal, pancreatic and hypophysial hormones including somatostatin in healthy volunteers
- Acarbose: an intestinal tract a-glucosidase inhibitor — pharmacological effects on insulin and glycemia in response to a sucrose load
- Assessment of efficacy and tolerability of acarbose (Glucobay<sup>®</sup>) by clinical data pool
- Long-term tolerability of acarbose
- Assessment of efficacy and tolerability of acarbose in diabetic patients 5 — 16 years of age
- Effect of acarbose repeated dosing on antipyrine test in healthy volunteers
- Discussion